Although it can happen in otherwise healthy hearts, Atrial Fibrillation is associated with a number of cardiovascular diseases. High blood pressure, coronary artery disease, mitral valve stenosis (caused, for example, by rheumatic heart disease or mitral valve prolapse), mitral regurgitation, left atrial enlargement, hypertrophic cardiomyopathy (HCM), pericarditis, congenital heart disease, and prior heart surgery are among the cardiovascular conditions known to be linked to the development of Atrial Fibrillation.
A 20-year-old adult with congenital heart disease has a comparable lifetime risk of acquiring atrial fibrillation to a 55-year-old adult without a history of congenital heart disease. Congenital heart disease is a significant risk factor for atrial fibrillation. Atrial fibrillation is more likely to be of right atrial origin (atypical) than of left atrial origin, start at an earlier age, and progress to permanent atrial fibrillation in those with congenital heart disease.
Although the majority of occurrences of Atrial Fibrillation are due to other medical conditions, an underlying cause may be present if there is chest discomfort or angina, hyperthyroidism (an overactive thyroid gland) symptoms like weight loss and diarrhoea, or lung disease symptoms. Someone with AF may be more susceptible to problems if they have a history of heart failure, rheumatic fever, high blood pressure, diabetes, or a stroke or transient ischemic attack (TIA).
However, lack of well-trained physicians and the high cost of treatments are hampering the atrial fibrillation market growth.Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=1541The report has provided a detailed profile of some of the leading players in the global atrial fibrillation market such as Abbott Laboratories, Biosense Webster, Inc., Medtronic Plc, MicroPort Scientific Corporation, Boston Scientific Corporation, Biotronik SE & Co. KG, CardioFocus, Inc., AtriCure Inc., Koninklijke Philips N.V., and Osypka AG.
The market is also estimated to reach US$ 10,925.1 million revenue by the end of 2026.On the basis of product type, the EP ablation catheters are expected to emerge as the most preferred product in the global atrial fibrillation market.
On the basis of end-user, the market is segmented into electrophysiology labs, hospitals, and ambulatory surgical center.
A maximum number of catheter ablation are performed in Germany.Buy Atrial Fibrillation Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=1541=SRise in the Use of Less Invasive and Advanced Treatment for Atrial FibrillationMajor hospitals and medical centers are using a less invasive procedure known as catheter ablation for treating atrial fibrillation.
It also has facilitated quick recovery than the surgery.
A recent study by the researchers at the Klinikum Coburg and the University of Utah Health also showed that radiofrequency catheter ablation lowered mortality rates in patients suffering from atrial fibrillation.
